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OBJECTIVES: To assess the cost-effectiveness, from the UK
NHS perspective, of magnetic resonance angiography (MRA),
duplex ultrasound (DUS) and computed tomography (CT) com-
pared with contrast angiography (CA) in assessing the extent and
location of stenosis and subsequently formulating a treatment
plan for patients with peripheral arterial disease (PAD).
METHODS: A probabilistic decision tree was developed in order
to estimate the cost per QALY (in £2004) associated with each
diagnostic method for assessment of the whole leg, and the arter-
ies above and below the knee. Input parameters were obtained
from a systematic review, other published sources and expert
opinion. Lack of data to extrapolate the results to a longer period
led to consideration of a 1-year time horizon, therefore dis-
counting was not performed. RESULTS: DUS was the dominant
strategy for the assessment of the whole leg, with a cost per
QALY of £13,646. MRA appeared to be more cost-effective for
assessment of the arteries above the knee, with a cost-per-QALY
equal to £8628 with 2D-TOF MRA, and an incremental cost per
additional QALY equal to £37,024 when 2D-TOF MRA was
compared to DUS. For below the knee comparisons, results were
uncertain, with DUS being more likely to be cost-effective at
commonly accepted cost-per-QALY threshold values. CON-
CLUSIONS: The cost-effectiveness of the diagnostic tests was
dependent on the area of the leg being assessed, with DUS being
dominant for comparisons of the whole leg and cost-effective for
below the knee comparisons, and MRA being cost-effective for
above the knee assessments.
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OBJECTIVES: Drug eluting stents (DES) are more effective than
bare metal stents (BMS) in preventing angiographic and clinical
restenosis. Within this study the cost-effectiveness of sirolimus
(SES) and paclitaxel eluting stents (PES) compared to BMS was
estimated for a UK setting with data from a meta-analysis.
METHODS: A probabilistic Markov model was constructed.
The model includes events observed in clinical trials (MI, revas-
cularisation, CABG) and the health states heart failure and
stroke. The meta-analysis data comprised 3-year follow-up data
from randomized controlled trials. Probability distributions were
ﬁtted to all transition probability, cost and quality of life (QoL)
parameters. Univariate sensitivity analysis was performed on
several parameters. Effects and costs were discounted at 3%, the
time horizon was 3 years and the number of stents was 1.27 per
patient. A health care perspective was adopted. QoL data was
obtained from published studies. RESULTS: The incremental
costs for SES patients are €712 (95% CI: −2431–1715) and
€1101 (95% CI: 150–1493) for PES patients. DES yield less
QALYs than BMS with −0.0156 incremental QALYs (95% CI:
−0.2652–0.2302) per SES patient and −0.0077 incremental
QALYS (95% CI: −0.0777–0.06643) per PES patient compared
to BMS patients. At a threshold level of Euros 50’000 per QALY
the incremental net monetary beneﬁt per SES patient is €−1492
(95% CI: −14213–10766) and €−1484 (95% CI: −5004–2273)
per PES patient. At the same threshold level SES have a 35%
probability of being cost-effective, PES have a probability of
17% of being cost-effective. CONCLUSIONS: Three-year
follow up data show that DES are less effective than BMS when
mortality is taken into account. Given the higher costs per DES
patient, DES are dominated by BMS. Althoug DES show
favourable results over BMS concerning revascularisation rates,
they are not cost-effective.
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OBJECTIVE: To determine the presence of cardiovascular events
(CVEs) and their association with the main cardiovascular risk
factors (CVRFs) and resource utilization parameters (direct
costs) in subjects with chronic obstructive pulmonary disease
(COPD) in different Spanish primary care centers. METHODS:
A retrospective-multicenter design was adopted, with inclusion
of the patients seen for COPD (ICPC:R95) by four primary care
teams and two hospitals during 2004. The main measures were:
age-sex, cardiovascular antecedents (ischemic heart disease
[IHD], cerebrovascular accident, hypertension, dyslipidemia,
diabetes mellitus, smoking, obesity) and other co-morbidities,
clinical parameters (FEV1, BMI), resources utilization (comple-
mentary tests, pharmaceutical prescription, specialist referral,
physician visits, hospitalizations and emergency-room visits,
ambulatory care) and costs (semiﬁxed and direct). A logistic
regression analysis was made to ﬁt the model. The costs were
contrasted by covariance analysis (ANCOVA-marginal means).
Data were analyzed using SPSS-v12 and p values of <0.05 were
taken as the level of statistical signiﬁcance. RESULTS: Nine-
hundred patients were seen for COPD; mean age 70.4 ± 9.8 years
and 85.3% were males. Around 19.0% (n = 171) had undergone
a CVE (CI: 16.4–21.6%); 15.1% with IHD. The main CVRFs
were: 44.1%-hypertension, 36.2%-obesity, 31.9%-dyslipidemia,
23.6%-diabetes and 22.7%-smoking. The mean morbidity/
patient/year was 10.1 ± 4.2 with CVEs vs. 8.3 ± 4.3 (p = 0.000);
the clinical parameters studied (FEV1, BMI) showed no signiﬁ-
cance. The logistic model, corrected for age-sex and severity
identiﬁed as associated factors: diabetes mellitus (OR = 2.1; 
CI = 1.3–3.4; p = 0.001) and dyslipidemia (OR = 1.7; CI =
1.1–2.7; p = 0.002). Quantiﬁcation of unit cost/year/COPD was
€2793.22 ± 3166.30 (70.5% pharmaceutical expenditure). The
cost/year/patient-adjusted was €2847.22 (SE = 117.02) without
CVEs, versus €2563.66 (SE = 244.05) with CVEs, p = NS. CON-
CLUSIONS: The presence of CVEs associated with COPD is
high, causing an important co-morbidity, though without
increasing the global costs of the disease. Diabetes mellitus and
dyslipidemia are the main CVRFs associated; their prevention
could improve the disease outcomes. Further studies are needed
to conﬁrm the consistency of these results.
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OBJECTIVES: In The Netherlands, costs of statin use have
recently increased sharply compared to costs of other drugs. Yet,
several studies have established undertreatment and overtreat-
